Stay updated on RMC-6236 in RAS Mutant Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page.

Latest updates to the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedAdded a new Locations section listing study sites in CA, FL, MD, MA, NY, OH, TN, TX, UT, and VA (v3.3.3). Removed the older v3.3.2 location subsections and the HHS Vulnerability Disclosure link.SummaryDifference1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe site footer revision label was updated from Revision: v3.3.1 to Revision: v3.3.2.SummaryDifference0.0%

- Check29 days agoChange DetectedEditorial updates were made to the PubMed publication note on the Study Details page to clarify auto-fill from PubMed, and the Revision label was updated to v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check37 days agoChange DetectedThe page now describes a Phase 1/2 multicenter open-label study of RMC-6236 with dose escalation and expansion cohorts to establish MTD/RP2D, enrolling up to 754 participants; it also clarifies the drug as a RAS-MULTI(ON) inhibitor targeting KRAS, NRAS, and HRAS mutations.SummaryDifference0.8%

- Check51 days agoChange DetectedThe study record content remains unchanged between versions, with only minor formatting differences observed in the screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check80 days agoChange DetectedPage now includes an official operating-status notice and updates version to v3.2.0, replacing v3.1.0.SummaryDifference4%

Stay in the know with updates to RMC-6236 in RAS Mutant Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page.